A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.

NCT04808154 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG: SNP-630

Sponsor

Sinew Pharma Inc.